Improved Patient Outcomes Facilitated by C-Peptide Testing, Enabling Reclassification and Therapeutic Changes for Patients with Diabetes - Labroots
High confidence: full text extraction produced 1487 characters.
Accurate classification of diabetes is essential for selecting appropriate treatment and improving patient outcomes, yet distinguishing type 1 diabetes (T1D) from type 2 diabetes (T2D) remains a significant clinical challenge.1
This webinar explores the role of C-peptide testing as an objective biomarker of endogenous insulin production and beta-cell function and highlights how C-peptide testing can support diabetes classification, guide treatment decisions, and identify individuals who may not require lifelong insulin therapy.
This session presents key findings from an ongoing Cardiff pilot study that evaluated 388 individuals clinically diagnosed with Type 1 Diabetes (T1D) for over three years who were antibody-negative or untested.
Attendees will learn how incorporating routine C-peptide testing improves diagnostic accuracy, enables personalized diabetes care, and drives institutional cost savings.
Learning Objectives:
Labroots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.
Group viewing options are available - see our CE credit page for more information.
1. American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S20-S42. doi:10.2337/dc24-S002.